OPE MADON WOOD

SEQUENCE LISTING

<110> VALTANEN, Heli et al.	
<120> METHOD FOR DESIGNING PEPTIDES	
<130> 0933-0238PUS1	
. <140> US 10/528,989 <141> 2005-03-24	
<150> PCT/FI2003/000705 <151> 2003-09-29	
<160> 27	
<170> PatentIn version 3.3	
<210> 1 <211> 30 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic intein Fwd SapI primer	
<400> 1 cctttctgct cttccaacgc cgacggggct	30
<210> 2 <211> 30 <212> DNA <213> Artificial Sequence	
<220> <223> Synthetic intein Rev PstI primer	
<400> 2 actttcaacc tgcagttacc cagcggcccc	30
<210> 3	
<220> <223> Synthetic oligonucleotide encoding SEQ ID NO: 10	
<400> 3 ggtggtgctc ttccaactgt acgacccatt ggggatttac tttatgttaa ctgcaggcg	59
<210> 4 <211> 15 <212> DNA	

```
<213> Artificial Sequence
<220>
<223> Synthetic primer used to convert SEQ ID NO: 3 to double-stranded form
<400> 4
cgcctgcagt taaca
                                                                    15
<210> 5
<211> 75
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic degenerate oligonucleotide used in the cloning of the intein-
      peptide fusions
<400> 5
ggtggttgct cttccaacgg ccgccvavva vtatvavggc tgtaccaccc atttacttta 60
tgttaactgc aggcg
<210> 6
<211> 17
<212> DNA
<213> Artificial Sequence
<223> Transposon specific primer
<400> 6
atcagcggcc gcgatcc
                                                                    17
<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Transposon specific primer
<400> 7
ttattcggtc gaaaaggatc c
                                                                    21
<210> 8
<211> 4
<212> PRT
<213> Unknown
<220>
<223> Peptide derived from phage
<400> 8
```

Ala Asp Gly Ala

```
1
```

<210> 13

```
<210> 9
<211> 4
<212> PRT
<213> Unknown
<220>
<223> Peptide derived from phage
<400> 9
Gly Ala Ala Gly
  1
<210> 10
<211> 10
<212> PRT
<213> Unknown
<223> CTT-peptide recombinantly prepared by the intein system
Cys Thr Thr His Trp Gly Phe Thr Leu Cys
<210> 11
<211> 10
<212> PRT
<213> Unknown
<220>
<223> Non-cyclic synthetic control peptide
Ser Thr Thr His Trp Gly Phe Thr Leu Ser
<210> 12
<211> 10.
<212> PRT .
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 2 of the
      CTT-peptide (SEQ ID: 10)
<400> 12
Cys Ala Thr His Trp Gly Phe Thr Leu Cys
                  5
                                      10
```

```
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 3 of the
      CTT-peptide (SEQ ID: 10)
<400> 13
Cys Thr Ala His Trp Gly Phe Thr Leu Cys
                  5
<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 4 of the
      CTT-peptide (SEQ ID: 10)
<400> 14
Cys Thr Thr Ala Trp Gly Phe Thr Leu Cys
                  5
<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 5 of the
      CTT-peptide (SEQ ID: 10)
<400> 15
Cys Thr Thr His Ala Gly Phe Thr Leu Cys
 1
                  5
<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 6 of the
      CTT-peptide (SEQ ID: 10)
<400> 16
Cys Thr Thr His Trp Ala Phe Thr Leu Cys
 1
                  5
<210> 17
<211> 10
```

```
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 7 of the
      CTT-peptide (SEQ ID: 10)
Cys Thr Thr His Trp Gly Ala Thr Leu Cys
                  5
<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 8 of a
      mutated CTT-peptide (SEQ ID: 10)
<400> 18
Cys Thr Thr His Trp Gly Phe Ala Leu
                  5
<210> 19
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Ala-substitution at residue 8 of the
      CTT-peptide (SEQ ID: 10)
<400> 19
Cys Thr Thr His Trp Gly Phe Ala Leu Cys
                  5
<210> 20
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      CTT-peptide with a tryptophan analogue at position 5
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa at position 5 is 5-OH-Trp, 5-F-Trp or 6-F-Trp
<400> 20
Cys Thr Thr His Xaa Gly Phe Thr Leu Cys
```

```
<210> 21
<211> 10
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Control sequence
<400> 21
Cys Glu Arg Gly Gly Leu Glu Thr Ser Cys
<210> 22
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Control sequence
<400> 22
Cys Pro Cys Phe Leu Leu Gly Cys Cys
<210> 23
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      CTT-peptide with additional hydrophilic amino acids at positions 2-6 and
      Gly at positions 1 and 7 which is aliphatic
<220>
<221> misc_feature
<222> (3)..(4)
<223> Xaa at positions 3 and 4 is any hydrophilic amino acid
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa at position 6 is any hydrophilic amino acid
<400> 23
Gly Arg Xaa Xaa Tyr Xaa Gly Cys Thr Thr His Trp Gly Phe Thr Leu
Cys
```

10

1

```
<210> 24
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      CTT-peptide of SEQ ID NO: 10 with additional hydrophilic amino acids at
      positions 2-6 and Gly at positions 1 and 7 which is aliphatic
Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu
Cys
<210> 25
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic peptide derived from phage
<220>
<221> misc feature
<222> (5)..(5)
<223> Xaa can be any naturally occurring amino acid and (X)n may be present or
       absent. Xaa at position 5 is the peptide insertion point.
<400> 25
Ala Asp Gly Ala Xaa Gly Ala Ala Gly
<210> 26
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: MMP-2 specific fluorescent peptide
       substrate
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is MCA
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is Nva
```

```
<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is Dpa
<400> 26
Xaa Pro Leu Ala Xaa Xaa Ala Arg
<210> 27
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: recombinant peptide prepared by the
      intein system
<400> 27
Cys Thr Thr His Trp Gly Phe Thr Ala Cys
               5
                                   10
```